Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Clark

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Health Technology Assessment (Winchester, England)|November 11, 2025
Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: CONFORM-OH pilot RCT and economic evaluationHelen Mossop, Sarah Al Ashmori, Tumi Sotire, et al.
Infancy : the Official Journal of the International Society on Infant Studies|May 15, 2026
Predicting Dyadic Synchrony: A Theory-Driven Machine Learning ApproachMichel Sfeir, Fabiola Silletti, Hung-Chu Lin, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
Frontiers in Microbiology|October 19, 2020
A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent <i>Clostridioides difficile</i> Infection in Pre-clinical ModelsApril K Roberts, Hannah C Harris, Michael Smith, et al.
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
BMJ Open|December 21, 2019
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocolEmma Clark, Miranda Morton, Shriya Sharma, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
JAMA Internal Medicine|March 18, 2024
Text vs Patient Portal Messaging to Improve Influenza Vaccination Coverage: A Health System-Wide Randomized Clinical TrialPeter G Szilagyi, O Kenrik Duru, Alejandra Casillas, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Health Technology Assessment (Winchester, England)|November 11, 2025
Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: CONFORM-OH pilot RCT and economic evaluationHelen Mossop, Sarah Al Ashmori, Tumi Sotire, et al.
Infancy : the Official Journal of the International Society on Infant Studies|May 15, 2026
Predicting Dyadic Synchrony: A Theory-Driven Machine Learning ApproachMichel Sfeir, Fabiola Silletti, Hung-Chu Lin, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
Frontiers in Microbiology|October 19, 2020
A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent <i>Clostridioides difficile</i> Infection in Pre-clinical ModelsApril K Roberts, Hannah C Harris, Michael Smith, et al.
The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.
BMJ Open|December 21, 2019
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocolEmma Clark, Miranda Morton, Shriya Sharma, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
JAMA Internal Medicine|March 18, 2024
Text vs Patient Portal Messaging to Improve Influenza Vaccination Coverage: A Health System-Wide Randomized Clinical TrialPeter G Szilagyi, O Kenrik Duru, Alejandra Casillas, et al.
Pageof 10